bioAffinity Technologies Presents Research Supporting CyPath Lung Processing Methods at CHEST 2025

bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today announced it will present research at CHEST 2025, the annual meeting of the American College of Chest Physicians. The study supports the methods used to collect and transport patient samples for analysis by the Company’s noninvasive CyPath Lung test for detecting early-stage lung cancer.

“Our research reflects the scientific rigor applied to every step of the CyPath Lung process that has been shown to result in clear, accurate and reliable answers when they matter most,” said Maria Zannes, President and CEO of bioAffinity Technologies, Inc. “We are proud to present our work at CHEST, a premier pulmonary conference that brings the world’s leading physicians together to discuss cutting-edge technology like our own CyPath Lung.”

Rossella Titone, PhD, project manager for product development at bioAffinity Technologies, will present the poster “The Effect of Sputum Storage and Shipping Temperature on Flow Cytometric Outcomes of Sputum-Based Diagnostic Tests” on October 22, 2025, at 10:20 a.m. at poster board #4324.

“This research supports the protocols we use for handling clinical samples collected at home by patients and returned to our laboratory for processing. Physicians usually receive results in two days,” said Gordon Downie, MD, PhD, Chief Medical Officer of bioAffinity Technologies. “Our recent announcements of multiple case studies in which lung cancer was found at potentially curative Stage 1A illustrates the value of the kind of research Dr. Titone is presenting at CHEST. We look forward to speaking with physicians and other healthcare professionals at CHEST about how CyPath Lung can result in better outcomes for patients.”

About CyPath Lung

CyPath Lung uses proprietary advanced flow cytometry and artificial intelligence (AI) to identify cell populations in patient sputum that indicate malignancy. Automated data analysis helps determine if cancer is present or if the patient is cancer-free. CyPath Lung incorporates a fluorescent porphyrin that is preferentially taken up by cancer and cancer-related cells. Clinical study results demonstrated that CyPath Lung had 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in patients at high risk for the disease who had small lung nodules less than 20 millimeters. Diagnosing and treating early-stage lung cancer can improve outcomes and increase patient survival. For more information, visit www.cypathlung.com.